key: cord-0890604-w22wzrju
authors: Solodky, M.L.; Galvez, C.; Russias, B.; Detourbet, P.; N’Guyen-Bonin, V.; Herr, A.-L.; Zrounba, P.; Blay, J.-Y.
title: Lower detection rates of SARS-COV2 antibodies in cancer patients vs healthcare workers after symptomatic COVID-19
date: 2020-05-01
journal: Ann Oncol
DOI: 10.1016/j.annonc.2020.04.475
sha: f9f4140c03944315ef6132391ad05cb55f769125
doc_id: 890604
cord_uid: w22wzrju

nan

The diagnosis of COVID-19 is based on the detection of the SARS-COV2 virus using RT-PCR from nasopharyngeal samples at the time of active infection (1-3). Most patients infected with SARS-COV2 develop antibodies (Ab) against SARS-COV2 proteins (1-3). The survival of cancer patients presenting with RT-PCR+ COVID-19 has been reported to be very poor, with up to 30% mortality at 30 days (4,5).

In this work, we retrospectively analyzed cancer patients presenting with a suspicion of COVID-19 from March 1st 2020 to April 16 th 2020 as part of an Institutional Review Board approved clinical trial (Oncovid-19, approved 12 March 2020) and a series of health care workers (HCWs, nurses and doctors) as part of a voluntary testing procedure in the Centre Leon Berard.

All 85 cancer patients were tested both with SARS-nCoV2 RT-PCR on nasopharyngeal samples and a point-of-care Ab diagnostic test, Toda Coronadiag® (TODA Pharma, Strasbourg France). Coronadiag® is a rapid lateral flow immunoassay (LFIA) providing results in 10 min using a finger-pricked blood sample. This test was performed 15 days or more after a positive RT-PCR or COVID-19 symptoms. The LFIA test was performed in all 244 HCWs. In addition, SARS-CoV2 RT-PCR was found positive previously (>15d) in 14 HCW presenting with clinical symptoms, and was performed in the 3 HCWs testing positive for SARS-COV2 Ab.

Ten of 85 (12%) of cancer patients had documented SARS-CoV2 on RT-PCR, and 5 (6%) had a positive Ab detection test. Three of the 10 (30%) RT-PCR-confirmed infected patients had detectable Ab anti SARS-COV2 15 days after the clinical start of the infection. Two of the 75 (2.3%) remaining cancer patients screening negative for RT-PCR had detectable SARS-COV2 IgG.

In parallel, all 244 HCW were tested with the LFIA test, including 14 with a RT-PCR-documented SARS-COV2 infection: 10 of these 14 (71%) RT-PCR-confirmed infections had detectable Abs 15 days or later after clinical symptoms. Three of the remaining 230 (1.3%) HCW had detectable Ab but a negative test for RT-PCR performed at the same time. Two of these reported possible COVID-19 symptoms in the previous weeks.

The rate of seroconversion 15 days after documented SARS-COV2 on RT-PCR was therefore significantly lower in cancer patients vs HCWs (30% vs 71%, p=0.04). Importantly, 6 of the 7 serodiagnostic-negative cancer patients had received cytotoxic therapy or major surgical intervention in the previous 4 weeks, compared to none of the 5 remaining patients (p=0.003). None of these patients died.

In this series, 5 of 85 (5.9%) and 13 of 244 (5.4%) of cancer patients and HCWs, respectively, had detectable Ab against COVID-19. However, cancer patients had a significantly lower detection rate of SARS-COV2 antibodies 15 days or later after symptoms and RT-PCR+ testing. Anti-SARS-COV2 Ab were more often undetectable in patients receiving cancer treatments in the month prior to testing. Additional studies will be needed to confirm whether immune response to the virus is influenced by recent cancer treatments.

Report from the American Society for Microbiology COVID-19 International Summit

Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19

Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan